Literature DB >> 22836352

Cerecyte coil trial: angiographic outcomes of a prospective randomized trial comparing endovascular coiling of cerebral aneurysms with either cerecyte or bare platinum coils.

Andrew J Molyneux1, Alison Clarke, Mary Sneade, Ziyah Mehta, Stuart Coley, Daniel Roy, David F Kallmes, Allan J Fox.   

Abstract

BACKGROUND AND
PURPOSE: We report the primary outcome of the Cerecyte Coil Trial, a randomized trial to determine whether polymer-loaded Cerecyte coils compared with Micrus bare platinum coils improved the proportion of patients with angiographic occlusion of the aneurysm at 6 months when assessed by a core laboratory. The secondary objectives were to compare the clinical outcomes and retreatment rates in the 2 groups.
METHODS: Five hundred patients between 18 and 70 years of age with a ruptured or unruptured target aneurysm were randomized to be treated with either Cerecyte or bare platinum coils in 23 centers worldwide. Two hundred forty-nine patients were assigned to Cerecyte coils and 251 to bare platinum coils. Analysis was by intention to treat.
RESULTS: Four hundred ninety-four patients were eligible for analysis. Four hundred eighty-one patients underwent coil treatment of their aneurysm, 227 patients with recently ruptured aneurysms and 254 with unruptured aneurysms. Four hundred thirty-three follow-up angiograms were assessed by the core laboratory; 127 of 215 (59%) and 118 of 218 (54%) in the Cerecyte and bare platinum groups, respectively, fulfilled the trial prespecified definition of success, namely that the treated aneurysm showed complete angiographic occlusion, had stable neck remnant, or improved in angiographic appearance compared with the end-of-treatment angiogram (P=0.17). Late retreatment was performed in 25 of 452 (5.5%) patients, 17 (7.7%) Cerecyte versus 8 (3.5%) bare platinum (P=0.064; range, 4-34 months). The clinical outcomes did not differ between the groups.
CONCLUSIONS: There was no significant difference at 6 months in the angiographic outcomes between Cerecyte coils and bare platinum coils when assessed by the core laboratory. Clinical Trial Registration Information- URL: www.controlled-trials.com. Unique Identifier: ISRCTN82461286.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836352     DOI: 10.1161/STROKEAHA.112.657254

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  31 in total

1.  In vitro performance of a shape memory polymer foam-coated coil embolization device.

Authors:  Anthony J Boyle; Mark A Wierzbicki; Scott Herting; Andrew C Weems; Adam Nathan; Wonjun Hwang; Duncan J Maitland
Journal:  Med Eng Phys       Date:  2017-07-31       Impact factor: 2.242

2.  Hydrogel versus Bare Platinum Coils in Patients with Large or Recurrent Aneurysms Prone to Recurrence after Endovascular Treatment: A Randomized Controlled Trial.

Authors:  J Raymond; R Klink; M Chagnon; S L Barnwell; A J Evans; J Mocco; B H Hoh; A S Turk; R D Turner; H Desal; D Fiorella; S Bracard; A Weill; F Guilbert; S Lanthier; A J Fox; T E Darsaut; P M White; D Roy
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-12       Impact factor: 3.825

3.  Geographic Differences in Endovascular Treatment and Retreatment of Cerebral Aneurysms.

Authors:  A S Turk; S C Johnston; S Hetts; J Mocco; J English; Y Murayama; C J Prestigiacomo; D Lopes; Y P Gobin; K Carroll; C McDougall
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-07       Impact factor: 3.825

4.  GREAT-a randomized aneurysm trial. Design of a randomized controlled multicenter study comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment.

Authors:  Christian Taschner; René Chapot; Vincent Costalat; Patrick Courthéoux; Xavier Barreau; Jerome Berge; Laurent Pierot; Kryzsztof Kadziolka; Betty Jean; Raphael Blanc; Alessandra Biondi; Hervé Brunel; Sophie Gallas; Ansgar Berlis; Denis Herbreteau; Joachim Berkefeld; Christoph Groden; Horst Urbach; Samer El Shikh; Erika Graf; Alain Bonafé
Journal:  Neuroradiology       Date:  2015-02-28       Impact factor: 2.804

5.  Counterpoint-target aneurysm recurrence: measuring what matters.

Authors:  C G McDougall; S C Johnston; A Gholkar; A S Turk
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-27       Impact factor: 3.825

6.  Counterpoint-response to "in memoriam: the matrix coil".

Authors:  A S Turk; D Fiorella; J Mocco; C Derdeyn
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-03       Impact factor: 3.825

7.  Point-TAR: a useful index to follow-up coiled intracranial aneurysms?

Authors:  L Pierot; J Fiehler; P White
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-27       Impact factor: 3.825

8.  Interobserver variability in retreatment decisions of recurrent and residual aneurysms.

Authors:  J S McDonald; R E Carter; K F Layton; J Mocco; J B Madigan; R G Tawk; R A Hanel; S S Roy; H J Cloft; A M Klunder; S H Suh; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-25       Impact factor: 3.825

9.  GREAT-a randomized controlled trial comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment: procedural safety and core-lab-assessedangiographic results.

Authors:  Christian A Taschner; René Chapot; Vincent Costalat; Paolo Machi; Patrick Courthéoux; Xavier Barreau; Jérôme Berge; Laurent Pierot; Kryzsztof Kadziolka; Betty Jean; Raphaël Blanc; Alessandra Biondi; Hervé Brunel; Sophie Gallas; Ansgar Berlis; Denis Herbreteau; Joachim Berkefeld; Horst Urbach; Samer El Shikh; Jens Fiehler; Hubert Desal; Erika Graf; Alain Bonafé
Journal:  Neuroradiology       Date:  2016-04-30       Impact factor: 2.804

10.  Endovascular treatment of 300 consecutive middle cerebral artery aneurysms: clinical and radiologic outcomes.

Authors:  A M Mortimer; M D Bradley; P Mews; A J Molyneux; S A Renowden
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-14       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.